Clinical trials: Advanced Cutaneous Melanoma
Melanoma Stage III, Melanoma Stage IV
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Trial name
- NCT04741997
- Testing
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors.
- Trial name
- NCT07287917
- Testing
- AMXT 1501 Dicaprate, DFMO, Fulvestrant
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Aminex Therapeutics, Inc.
Advanced Renal Cell Carcinoma, Advanced Melanoma
Sitagliptin With Pembro in RCC and Melanoma
This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped…
- Trial name
- NCT07634380
- Testing
- Sitagliptin, Pembrolizumab
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Fernando Maciel Barbosa
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body.
- Conditions
- Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03727789
- Testing
- FACT Complex-targeting Curaxin CBL0137
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Melanoma
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
The purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and metastatic melanoma.
- Trial name
- CHIR-265-MEL01 (NCT00304525)
- Testing
- RAF265
- Where
- 11 sites in United States, Switzerland
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Melanoma Recurrent, Malignant Melanoma
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
This is an open label Pilot study to evaluate the combination of Vigil™ and pembrolizumab in patients with incurable locally advanced or metastatic melanoma.
- Conditions
- Melanoma Recurrent, Malignant Melanoma, Melanoma
- Trial name
- NCT02574533
- Testing
- Vigil, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Gradalis, Inc.
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin), Squamous Cell Carcinoma of the Skin
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic
- Trial name
- NCT03291002
- Testing
- CV8102, CV8102 + anti-PD-1 therapy
- Where
- 22 sites in Austria, France and 3 more
- Volunteers
- 98 people
- Sponsor
- CureVac
Melanoma
CAcTUS - Circulating Tumour DNA Guided Switch
The stay aims to determine whether switching from targeted therapy to immunotherapy based on a decrease in levels of circulating tumour DNA in the blood, will improve the outcome in melanoma patients.
- Trial name
- CAcTUS (NCT03808441)
- Testing
- ctDNA analysis
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Christie NHS Foundation Trust
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Uveal Melanoma, Metastatic
PHP and Immunotherapy in Metastasized UM
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs.
- Trial name
- CHOPIN (NCT04283890)
- Testing
- Ipilimumab and nivolumab, Melphalan chemosaturation via percutaneous hepatic perfusion
- Where
- Netherlands
- Volunteers
- 83 people
- Sponsor
- Leiden University Medical Center
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
Malignant Melanoma
Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma
Primary objective: Determination of safety and tolerability of GV1001 administration combined with Temozolomide (based on blood samples and adverse events).
- Trial name
- NCT01247623
- Testing
- GV1001
- Where
- Norway
- Sponsor
- Oslo University Hospital
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Advanced Melanoma
Nab-PCE vs PC for MM After Failure of Anti-PD-1
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin Endostatin for advanced melanoma after failure of PD-1 therapy.
- Trial name
- NCT03917069
- Testing
- Chemotherapeutic Combinations, chemotherapy
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Peking University Cancer Hospital & Institute